CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals (original) (raw)

References

  1. Douek, D.C., Picker, L.J. & Koup, R.A. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21, 265–304 (2003).
    Article CAS Google Scholar
  2. Rodriguez, B. et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. J. Am. Med. Assoc. 296, 1498–1506 (2006).
    Article CAS Google Scholar
  3. Dolan, M.J. et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry–independent mechanisms. Nat. Immunol. 8, 1324–1336 (2007).
    Article CAS Google Scholar
  4. Moore, R.D. & Keruly, J.C. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin. Infect. Dis. 44, 441–446 (2007).
    Article Google Scholar
  5. Grabar, S. et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133, 401–410 (2000).
    Article CAS Google Scholar
  6. Tarwater, P.M. et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27, 168–175 (2001).
    Article CAS Google Scholar
  7. Hunt, P.W. et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17, 1907–1915 (2003).
    Article Google Scholar
  8. Moore, D.M. et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J. Acquir. Immune Defic. Syndr. 40, 288–293 (2005).
    Article Google Scholar
  9. Valdez, H. et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 16, 1859–1866 (2002).
    Article CAS Google Scholar
  10. Kaufmann, G.R. et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1–infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41, 361–372 (2005).
    Article Google Scholar
  11. Podlekareva, D. et al. Factors associated with the development of opportunistic infections in HIV-1–infected adults with high CD4+ cell counts: a EuroSIDA study. J. Infect. Dis. 194, 633–641 (2006).
    Article Google Scholar
  12. Mehandru, S. et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 3, e484 (2006).
    Article Google Scholar
  13. Deeks, S.G., Barbour, J.D., Martin, J.N., Swanson, M.S. & Grant, R.M. Sustained CD4+ T cell response after virologic failure of protease inhibitor–based regimens in patients with human immunodeficiency virus infection. J. Infect. Dis. 181, 946–953 (2000).
    Article CAS Google Scholar
  14. Ledergerber, B. et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1–infected individuals with virological failure to all three antiretroviral drug classes. Lancet 364, 51–62 (2004).
    Article Google Scholar
  15. Deeks, S.G. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. J. Am. Med. Assoc. 286, 224–226 (2001).
    Article CAS Google Scholar
  16. Kaufmann, G.R. et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163, 2187–2195 (2003).
    Article Google Scholar
  17. Garcia, F. et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J. Acquir. Immune Defic. Syndr. 36, 702–713 (2004).
    Article Google Scholar
  18. Tenorio, A.R. et al. HIV-1–infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J. Acquir. Immune Defic. Syndr. 34, 491–496 (2003).
    Article Google Scholar
  19. Anastos, K. et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann. Intern. Med. 140, 256–264 (2004).
    Article CAS Google Scholar
  20. Grabar, S. et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 39, 284–292 (2005).
    Article Google Scholar
  21. Zhang, Z.Q. et al. The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P. Virology 320, 75–84 (2004).
    Article CAS Google Scholar
  22. Mellors, J.W. et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946–954 (1997).
    Article CAS Google Scholar
  23. Lifson, J.D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584–2593 (2000).
    Article CAS Google Scholar
  24. Nibbs, R.J., Yang, J., Landau, N.R., Mao, J.H. & Graham, G.J. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity. J. Biol. Chem. 274, 17478–17483 (1999).
    Article CAS Google Scholar
  25. Gonzalez, E. et al. Race-specific HIV-1 disease–modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. USA 96, 12004–12009 (1999).
    Article CAS Google Scholar
  26. Mangano, A. et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J. Infect. Dis. 183, 1574–1585 (2001).
    Article CAS Google Scholar
  27. Gonzalez, E. et al. The influence of CCL3L1 gene–containing segmental duplications on HIV-1/AIDS susceptibility. Science 307, 1434–1440 (2005).
    Article CAS Google Scholar
  28. Martin, M.P. et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282, 1907–1911 (1998).
    Article CAS Google Scholar
  29. Kaslow, R.A., Dorak, T. & Tang, J.J. Influence of host genetic variation on susceptibility to HIV type 1 infection. J. Infect. Dis. 191 (Suppl 1), S68–S77 (2005).
    Article Google Scholar
  30. Carrington, M. & O'Brien, S.J. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535–551 (2003).
    Article CAS Google Scholar
  31. Nguyen, L. et al. Frequent human leukocyte antigen class I alleles are associated with higher viral load among HIV type 1 seroconverters in Thailand. J. Acquir. Immune Defic. Syndr. 37, 1318–1323 (2004).
    Article CAS Google Scholar
  32. Rauch, A. et al. HLA-Bw4 homozygosity is associated with an impaired CD4-T-cell recovery after initiation of antiretroviral therapy. Clin. Infect. Dis. (in the press).
  33. Brumme, Z.L. et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195, 1694–1704 (2007).
    Article CAS Google Scholar
  34. Moore, D.M. et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 20, 371–377 (2006).
    Article CAS Google Scholar
  35. Weber, R. et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166, 1632–1641 (2006).
    Article Google Scholar
  36. Gutierrez, F. et al. Clinical Outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS ONE 1, e89 (2006).
    Article Google Scholar
  37. El-Sadr, W.M. et al. CD4+ count–guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283–2296 (2006).
    Article CAS Google Scholar
  38. Lewden, C. et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 46, 72–77 (2007).
    Article Google Scholar
  39. Valdez, H., Purvis, S.F., Lederman, M.M., Fillingame, M. & Zimmerman, P.A. Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy. J. Am. Med. Assoc. 282, 734 (1999).
    Article CAS Google Scholar
  40. Yamashita, T.E. et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 15, 735–746 (2001).
    Article CAS Google Scholar
  41. Kasten, S. et al. Positive influence of the Δ32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1–infected patients. Eur. J. Med. Res. 5, 323–328 (2000).
    CAS PubMed Google Scholar
  42. O'Brien, T.R. et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 14, 821–826 (2000).
    Article CAS Google Scholar
  43. Holmberg, S.D., Palella, F.J., Jr, Lichtenstein, K.A. & Havlir, D.V. The case for earlier treatment of HIV infection. Clin. Infect. Dis. 39, 1699–1704 (2004).
    Article Google Scholar
  44. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1–128 <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGl.pdf>, accessed 29 February 2008 (Department of Health and Human Services, 29 January 2008).
  45. Pahwa, S. Role of common γ chain–utilizing cytokines for immune reconstitution in HIV infection. Immunol. Res. 38, 373–386 (2007).
    Article CAS Google Scholar
  46. Hecht, F.M. et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194, 725–733 (2006).
    Article Google Scholar
  47. Saah, A.J. et al. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. AIDS 12, 2107–2113 (1998).
    Article CAS Google Scholar
  48. Kaslow, R.A. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2, 405–411 (1996).
    Article CAS Google Scholar
  49. Tang, J. et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 16, 2275–2284 (2002).
    Article Google Scholar
  50. Carrington, M., Nelson, G. & O'Brien, S.J. Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol. Lett. 79, 131–140 (2001).
    Article CAS Google Scholar

Download references

Acknowledgements

The people and funding agencies that made this work possible are listed in the Acknowledgements section in the Supplementary information online.

Author information

Author notes

  1. Hemant Kulkarni, Gabriel Catano and Brian K Agan: These authors contributed equally to this work.

Authors and Affiliations

  1. Veterans Administration Research Center for AIDS and HIV-1 Infection, South Texas Veterans Health Care System, 7400 Merton Minter, San Antonio, 78229, Texas, USA
    Sunil K Ahuja, Hemant Kulkarni, Gabriel Catano, Jose F Camargo, Weijing He, Robert A Clark & Seema S Ahuja
  2. Department of Medicine, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, 78229, Texas, USA
    Sunil K Ahuja, Hemant Kulkarni, Gabriel Catano, Jose F Camargo, Weijing He, Robert A Clark & Seema S Ahuja
  3. Departments of Microbiology and Immunology and Biochemistry, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, 78229, Texas, USA
    Sunil K Ahuja
  4. Infectious Disease Clinical Research Program, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, 20814, Maryland, USA
    Brian K Agan, Robert J O'Connell, Vincent C Marconi, Judith Delmar & Matthew J Dolan
  5. Infectious Diseases Service, Wilford Hall United States Air Force Medical Center, 2200 Bergquist Drive, Lackland Air Force Base, 78236, Texas, USA
    Brian K Agan, Robert J O'Connell, Vincent C Marconi, Judith Delmar & Matthew J Dolan
  6. Henry M. Jackson Foundation, Wilford Hall United States Air Force Medical Center, 2200 Bergquist Drive, Lackland Air Force Base, 78236, Texas, USA
    Brian K Agan & Matthew J Dolan
  7. San Antonio Military Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, 78234, Texas, USA
    Brian K Agan, Vincent C Marconi, Judith Delmar & Matthew J Dolan
  8. University of North Carolina, 4030 Bondurant Hall, Chapel Hill, 27599, North Carolina, USA
    Joseph Eron
  9. Department of Medicine, Antiviral Research Center, University of California, 150 West Washington Street, San Diego, 92103, California, USA
    Simon Frost, Susan Little & Douglas Richman
  10. Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, 92161, California, USA
    Simon Frost & Douglas Richman
  11. Department of Epidemiology and Biostatistics, University of California, 185 Berry Street, San Francisco, 94107, California, USA
    Jeffrey Martin
  12. Department of Medicine, San Francisco General Hospital, University of California–San Francisco, 995 Potrero Avenue, San Francisco, 94110, California, USA
    Steven G Deeks & Frederick M Hecht

Authors

  1. Sunil K Ahuja
  2. Hemant Kulkarni
  3. Gabriel Catano
  4. Brian K Agan
  5. Jose F Camargo
  6. Weijing He
  7. Robert J O'Connell
  8. Vincent C Marconi
  9. Judith Delmar
  10. Joseph Eron
  11. Robert A Clark
  12. Simon Frost
  13. Jeffrey Martin
  14. Seema S Ahuja
  15. Steven G Deeks
  16. Susan Little
  17. Douglas Richman
  18. Frederick M Hecht
  19. Matthew J Dolan

Contributions

S.K.A., H.K. and M.J.D. conceptualized the research, conducted statistical analyses, analyzed the data and wrote the manuscript. G.C., B.K.A., J.F.C., W.H., R.J.O., V.C.M., J.D., J.E., R.A.C., S.F., J.M., S.S.A., S.G.D., S.L., D.R., and F.M.H. made substantial contributions to conceptual ideas, experimental data, analysis of data, preparation of the manuscript and/or cohort data and development. S.K.A. and M.J.D. directed the study and obtained the funding for the genetic work.

Corresponding authors

Correspondence toSunil K Ahuja or Matthew J Dolan.

Supplementary information

Rights and permissions

About this article

Cite this article

Ahuja, S., Kulkarni, H., Catano, G. et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals.Nat Med 14, 413–420 (2008). https://doi.org/10.1038/nm1741

Download citation